Skip to main content

Advertisement

SpringerLink
Log in

Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To determine the safety and the efficacy of paclitaxel and capecitabine as second-line combination chemotherapy after failure of platinum regimens in advanced gastric cancer.

Methods

Patients with histologically proven gastric cancer and measurable metastatic disease received capecitabine 825 mg/m2 twice daily (1,650 mg/m2 per day) on days 1–14 and paclitaxel 175 mg/m2 by intravenous infusion on day 1 every 3 weeks until disease progression or unacceptable toxicities.

Results

Between June 2003 and October 2005, 26 patients, of median age 59 years (range 41–84 years) were included in the study and were treated by paclitaxel/capecitabine combination. Overall response rate was 34.6% (95%CI = 17.2–55.7%) with one complete response and 42.3% (95%CI = 17.2–55.7%) of patients achieved a stable disease. Median progression-free survival was 4.5 months (95%CI = 4–4.5 months). Median overall survival was 7.5 months (95%CI = 6–10 months). Cumulated overall survival including cisplatin regimens was 15.5 months (95%CI = 11–18 months). Grade 3/4 adverse events included alopecia (30.8%), neutropenia (11.5%), hand foot skin reaction (11.5%), neuropathy (11.5%), arthralgias (7.5%), and anemia (3.8%).

Conclusions

Paclitaxel and capecitabine combination was safe and effective in advanced gastric cancer after failure of cisplatin regimens. The cumulated overall survival of 15.5 months suggests a particular interest of taxanes in second-line treatment after failure of platinum salts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kamangar F, Dores GM, Anderson WE (2006) Patterns of cancer incidence, mortality and prevalence across 5 continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2537–2550

    Article  Google Scholar 

  2. Crew KD, Neugut AI (2006) Epidemiology of gastric cancer. World J Gastroenterol 12:354–362

    PubMed  Google Scholar 

  3. Dupont JB, Lee JR, Burton GR, Cohn I Jr (1978) Adenocarcinoma of the stomach: review of 1497 cases. Cancer 41:941–953

    Article  PubMed  Google Scholar 

  4. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M (1993) Modified therapy with 5 fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37–41

    Article  PubMed  CAS  Google Scholar 

  5. Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoden PO (1994) Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5:189–190

    PubMed  CAS  Google Scholar 

  6. Pyrhonen S, Kuitunen T, Nynandoto P, Kouri M (1995) Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587–591

    PubMed  CAS  Google Scholar 

  7. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163–168

    Article  PubMed  CAS  Google Scholar 

  8. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903–2909

    Article  PubMed  CAS  Google Scholar 

  9. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani J (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24:4991–4997

    Article  PubMed  Google Scholar 

  10. Chang YF, Li LL, Wu CW, Liu WY, P’eng FK, Chi CW (1996) Paclitaxel induced apoptosis in human gastric carcinoma cell lines. Cancer 77:14–18

    Article  PubMed  CAS  Google Scholar 

  11. Maeda S, Saikawa Y, Kubota T, Aoki M, Otani Y, Furukawa T, Watanabe M, Kumai K, Kitajima M (2003) No cross-resistance of taxotere and taxol to conventional chemotherapeutic agents against gastric cancers as detected by MTT assay. Anticancer Res 23:3147–3150

    PubMed  CAS  Google Scholar 

  12. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol 45:291–297

    Article  PubMed  Google Scholar 

  13. Ajani J (2006) Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 107:221–231

    Article  PubMed  CAS  Google Scholar 

  14. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4:1013–1019

    PubMed  CAS  Google Scholar 

  15. Villalona-Calero MA, Blum JL, Jones SE, Diab S, Elledge R, Khoury P, Von Hoff D, Kraynak M, Moczygemba J, Kromelis P, Griffin T, Rowinsky EK (2001) A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients. Ann Oncol 12:605–614

    Article  PubMed  CAS  Google Scholar 

  16. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O’Brien M, Iveson T, Watson M, Underhill C, Meehan M (1997) Randomized trial comparing epirubicin, cisplatin, and 5 fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261–267

    PubMed  CAS  Google Scholar 

  17. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18:2648–2657

    PubMed  CAS  Google Scholar 

  18. Fleming TR (1982) One sample multiple testing procedures for phase II clinical trials. Biometrics 43:143–151

    Article  Google Scholar 

  19. Park JM, Jang YJ, Kim JH, Park SS, Park SH, Kim SJ, Mok YJ, Kim CS (2008) Gastric cancer histology: clinicopathologic characteristics and prognosis value. J Surg Oncol 98:520–525

    Article  PubMed  Google Scholar 

  20. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti EP, Catalano G (1998) Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 9:307–310

    Article  PubMed  CAS  Google Scholar 

  21. Yamaguchi K, Tada M, Horikoshi N, Otani T, Takuichi H, Saitoh S, Kanamaru R, Kasai Y, Koizumi W, Sakata Y, Taguchi T (2002) Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 5:90–95

    Article  PubMed  CAS  Google Scholar 

  22. Kodera Y, Ito S, Mochizuchi Y, Fujitake S, Koshikawa K, Kanyama Y, Matsui T, Kojima H, Takase T, Ohashi N, Fujiwara M, Sakamoto J, Akimasa N, Chubu Clinical Cancer Group (2007) A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer. Cancer 27:2267–2271

    Google Scholar 

  23. Hong SY, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS, Cho JY (2004) A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 15:1344–1347

    Article  PubMed  CAS  Google Scholar 

  24. Sakamoto J, Chin K, Kondo K, Kojima H, Terashima M, Yamamura Y, Tsujinoka T, Hyodo I, Koizumi W, Clinical Study Group of Capecitabine (2006) Phase II study of a 4-week capecitabin regimen in advanced or recurrent gastric cancer. Anticancer Drugs 17:231–236

    Article  PubMed  CAS  Google Scholar 

  25. Koizumi W, Saigenji K, Ujiie S, Terashima M, Sakata Y (2003) Taguchi T Clinical Study Group of Capecitabine: a pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 64:232–236

    Article  PubMed  CAS  Google Scholar 

  26. Kang HJ, Chang HM, Kim TW, Ryu MH, Sohn HJ, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK (2008) A phase II study of paclitaxel and capecitabine as first-line combination chemotherapy for advanced gastric cancer. Br J Cancer 98:316–322

    Article  PubMed  CAS  Google Scholar 

  27. Gustalla JPIII, Diéras V (2003) The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer 89:S16–S22

    Article  Google Scholar 

  28. Rosati G, Bilancia D, Germano D, Dinota A, Romano R, Reggiardo G, Manzione L (2007) Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study. Ann Oncol 18:128–132

    Article  Google Scholar 

  29. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L, Bokemeyer C (2000) A phase II study of paclitaxel, weekly, 24-h continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 83:458–462

    Article  PubMed  CAS  Google Scholar 

  30. Im CK, Jeung HC, Rha SY, Yoo NC, Noh SH, Roh JK, Chung HC (2008) A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. Cancer Chemother Pharmacol 61:315–321

    Article  PubMed  CAS  Google Scholar 

  31. Lee HJ, Cho do Y, Park JC, Bae SB, Lee KT, Cho IS, Han CS, Park SY, Yun HJ, Kim S (2009) Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer. Cancer Chemother Pharmacol 63:427–432

    Article  PubMed  CAS  Google Scholar 

  32. Ajani JA (2008) Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastrooesophageal junction. Cancer 113:945–965

    Article  PubMed  CAS  Google Scholar 

  33. Park SH, Lee WK, Chung M, Lee Y, Han SH, Bang SM, Cho EK, Shin DB, Lee JH (2006) Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs 17:225–229

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Department of Oncology, University of Nice, Nice, France

    N. Baize, A. Abakar-Mahamat, N. Mounier & F. X. Caroli-Bosc

  2. Biostatistic Department, University of Nice, Nice, France

    F. Berthier

  3. CHU Angers, 4 rue Larrey, 49933, Angers Cedex 9, France

    F. X. Caroli-Bosc

Authors
  1. N. Baize
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Abakar-Mahamat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Mounier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Berthier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. X. Caroli-Bosc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. X. Caroli-Bosc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baize, N., Abakar-Mahamat, A., Mounier, N. et al. Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. Cancer Chemother Pharmacol 64, 549–555 (2009). https://doi.org/10.1007/s00280-008-0903-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-008-0903-7

Keywords

Search

Navigation